| Published Application/Species/Sample/Dilution | Reference |
|---|
| Jiang Y, Yuan Y, Chen M, Li S, Bai J, Zhang Y, et al. PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression. Theranostics. 2021;11:9162-9176 pubmed publisher |
- flow cytometry; mouse; loading ...; fig s2d
| Gangoso E, Southgate B, Bradley L, Rus S, Gálvez Cancino F, McGivern N, et al. Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion. Cell. 2021;184:2454-2470.e26 pubmed publisher |
- flow cytometry; mouse; loading ...; fig 4c
| Chen Z, Ji Z, Ngiow S, Manne S, Cai Z, Huang A, et al. TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision. Immunity. 2019;51:840-855.e5 pubmed publisher |
| Swan S, Mehta N, Ilich E, Shen S, Wilkinson D, Anderson A, et al. IL7 and IL7 Flt3L co-expressing CAR T cells improve therapeutic efficacy in mouse EGFRvIII heterogeneous glioblastoma. Front Immunol. 2023;14:1085547 pubmed publisher |
| Scherer S, Oberle S, Kanev K, Gerullis A, Wu M, de Almeida G, et al. Pyrimidine de novo synthesis inhibition selectively blocks effector but not memory T cell development. Nat Immunol. 2023;24:501-515 pubmed publisher |
| Zhao K, Ren C, Tang D, Zhao L, Chen X, Wang Y, et al. The altering cellular components and function in tumor microenvironment during remissive and relapsed stages of anti-CD19 CAR T-cell treated lymphoma mice. Front Immunol. 2023;14:1101769 pubmed publisher |
| Naranjo S, Cabana C, Lafave L, Romero R, Shanahan S, Bhutkar A, et al. Modeling diverse genetic subtypes of lung adenocarcinoma with a next-generation alveolar type 2 organoid platform. Genes Dev. 2022;36:936-949 pubmed publisher |
| Backlund C, Holden R, Moynihan K, Garafola D, Farquhar C, Mehta N, et al. Cell-penetrating peptides enhance peptide vaccine accumulation and persistence in lymph nodes to drive immunogenicity. Proc Natl Acad Sci U S A. 2022;119:e2204078119 pubmed publisher |
| Qi Z, Xu Z, Zhang L, Zou Y, Li J, Yan W, et al. Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment. Nat Commun. 2022;13:182 pubmed publisher |
| Burger M, Cruz A, Crossland G, Gaglia G, Ritch C, Blatt S, et al. Antigen dominance hierarchies shape TCF1+ progenitor CD8 T cell phenotypes in tumors. Cell. 2021;184:4996-5014.e26 pubmed publisher |
| Schenkel J, Herbst R, Canner D, Li A, Hillman M, Shanahan S, et al. Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1+ CD8+ T cells in tumor-draining lymph nodes. Immunity. 2021;54:2338-2353.e6 pubmed publisher |
| Poillet Perez L, Sharp D, Yang Y, Laddha S, Ibrahim M, Bommareddy P, et al. Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune response. Nat Cancer. 2020;1:923-934 pubmed publisher |
| Freed Pastor W, Lambert L, Ely Z, Pattada N, Bhutkar A, Eng G, et al. The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. Cancer Cell. 2021;: pubmed publisher |
| Di Pilato M, Kfuri Rubens R, Pruessmann J, Ozga A, Messemaker M, Cadilha B, et al. CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment. Cell. 2021;: pubmed publisher |
| Gabriel S, Tsui C, Chisanga D, Weber F, Llano Le xf3 n M, Gubser P, et al. Transforming growth factor-β-regulated mTOR activity preserves cellular metabolism to maintain long-term T cell responses in chronic infection. Immunity. 2021;54:1698-1714.e5 pubmed publisher |
| Wagle M, Vervoort S, Kelly M, Van Der Byl W, Peters T, Martin B, et al. Antigen-driven EGR2 expression is required for exhausted CD8+ T cell stability and maintenance. Nat Commun. 2021;12:2782 pubmed publisher |
| Mitchell J, Lund M, Starmer J, Ge K, Magnuson T, Shpargel K, et al. UTX promotes CD8+ T cell-mediated antiviral defenses but reduces T cell durability. Cell Rep. 2021;35:108966 pubmed publisher |
| Uzhachenko R, Bharti V, Ouyang Z, Blevins A, Mont S, Saleh N, et al. Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors. Cell Rep. 2021;35:108944 pubmed publisher |
| Chen Z, Arai E, Khan O, Zhang Z, Ngiow S, He Y, et al. In vivo CD8+ T cell CRISPR screening reveals control by Fli1 in infection and cancer. Cell. 2021;184:1262-1280.e22 pubmed publisher |
| Dammeijer F, van Gulijk M, Mulder E, Lukkes M, Klaase L, Van den Bosch T, et al. The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes. Cancer Cell. 2020;38:685-700.e8 pubmed publisher |
| Mirando A, Patil A, Rafie C, Christmas B, Pandey N, Stearns V, et al. Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide. Oncoimmunology. 2020;9:1760685 pubmed publisher |
| Beltra J, Manne S, Abdel Hakeem M, Kurachi M, Giles J, Chen Z, et al. Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms. Immunity. 2020;52:825-841.e8 pubmed publisher |
